Breaking News

CEL-SCI Corporation Completes Commissioning of Multikine Facility

Marks a key milestone that is a prerequisite to filing a Biologics License Application with the FDA and other regulators for marketing approval.

Author Image

By: Charlie Sternberg

Associate Editor

CEL-SCI Corporation’s Multikine (Leukocyte Interleukin, Injection) cGMP dedicated manufacturing facility commissioning has been completed—marking a milestone in bringing Multikine to market.   “The high degree of complexity involved in manufacturing Multikine has required tremendous investment and time on CEL-SCI’s part. Our manufacturing trade secret, capability, and know-how are high-value key strategic assets that would be very difficult for others to replicate. This achievement marks...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters